| Effect of Digital Payment to Campaign Health Workers on Vaccination Coverage (NCT05684081) | Makerere University | 2022-07-01 |
| Immunogenicity and Safety of the Booster Dose of Polio Vaccine With Different Primary Sequential Schedules in China (NCT04576910) | Zhejiang Provincial Center for Disease Control and Prevention | 2020-11-05 |
| Comparison of Immunogenicity of Inactivated Poliovirus Vaccine (IPV) Administered Intramuscularly or Intradermally (NCT04027036) | Instituto Nacional de Saúde, Mozambique | 2020-08-06 |
| Observational Program, Study the Preventive Efficacy of the BiVac Polio Vaccine Against the Incidence of Acute Respiratory Infections, Including COVID-19 (NCT05083039) | Chumakov Federal Scientific Center for Research and Development of Immune-and-Biological Products | 2020-05-14 |
| Inactivated Poliovirus Vaccine (IPV) With or Without E.Coli Double Mutant Heat-Labile Toxin (dmLT) Challenge Study in Healthy Adults (NCT04232943) | PATH | 2020-01-22 |
| Environmental Surveillance (ES) for Polio and AMR Using the TaqMan Array Card (NCT03818477) | University of Virginia | 2019-06-09 |
| Evaluation of Safety, Reactogenicity and Immunogenicity of Fractional-dose Inactivated Polio Vaccine (fIPV) Given Intradermally With Double Mutant Enterotoxigenic Escherichia Coli Heat Labile Toxin (dmLT) Adjuvant (NCT03922061) | University of Vermont | 2019-03-19 |
| Evaluation of an Infant Immunization Encouragement Program in Nigeria (NCT03870061) | GiveWell | 2018-07-01 |
| Mobile Phone SMS Messages and Automated Calls in Improving Vaccine Coverage Among Children in Pakistan (NCT03341195) | Aga Khan University | 2018-01-01 |
| Evaluation of Integrating MIYCN Interventions in Existing CGPP of PCI (NCT03368885) | FHI 360 | 2017-12-01 |
| Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (Phase Ib) (NCT04264546) | Jiangsu Province Centers for Disease Control and Prevention | 2017-11-24 |
| Safety and Immunogenicity of a Sabin Inactivated Poliovirus Vaccine (NCT04264598) | Jiangsu Province Centers for Disease Control and Prevention | 2017-08-21 |
| Immunogenicity and Safety Evaluation of Different Sequential Immunization Strategies by Sabin IPV and bOPV in Chinese Infants (NCT03147560) | Zhejiang Provincial Center for Disease Control and Prevention | 2017-05-02 |
| DTaP-IPV-HB-PRP-T Combined Vaccine as a Primary Series and a Second Year of Life Booster in HIV-Exposed Infected and Uninfected Infants (NCT02817451) | Sanofi Pasteur, a Sanofi Company | 2016-07-14 |
| Evaluating a Caregiver SMS Reminder Intervention to Reduce Immunization Drop-out in Arua, Uganda (NCT04177485) | Centers for Disease Control and Prevention | 2016-02-01 |
| OPV Transmissibility in Communities After Cessation of Routine OPV Immunization (NCT02376374) | Stanford University | 2015-02-01 |
| Safety Study of a Single Dose of Monovalent High-dose Inactivated Poliovirus Type 2 Vaccine (m-IPV2 HD) in Infants Early in Life (NCT02111135) | Vaxtrials S.A. | 2014-04-01 |
| Safety and Immunogenicity Study of Influenza Vaccines in HIV-infected and HIV-uninfected Pregnant Women in Western Kenya (NCT01810731) | Centers for Disease Control and Prevention | 2014-04-01 |
| Study of IMOVAX POLIO® Subcutaneous as a Booster Vaccine in Pre-school Age Children in Japan (NCT02005536) | Sanofi Pasteur, a Sanofi Company | 2013-12-01 |
| To Develop, Implement and Evaluate the Polio Demonstration Project Comprising of a Community Based Intervention Package for Polio Eradication in Pakistan (NCT01908114) | Aga Khan University | 2013-07-01 |
| Immunogenicity of 1 or 2 Doses of bOPV in Chilean Infants Primed With IPV Vaccine (NCT01841671) | University of Chile | 2013-04-01 |
| Pakistan Short Interval mOPV1 Compared With Standard Interval mOPV1 and bOPV 1,3 (NCT01586572) | Aga Khan University | 2012-04-01 |
| Polio NID and Routine EPI Integration Trial Pakistan (NCT01697280) | Aga Khan University | 2012-04-01 |
| Evaluation of Buffer on Immune Response to Oral Polio Vaccine (OPV) in Bangladesh (NCT01579825) | Johns Hopkins Bloomberg School of Public Health | 2012-04-01 |
| Safety of PENTAXIM® Given as a Three-Dose Primary Vaccination at 2, 3, and 4 Months of Age in Infants in China (NCT01491087) | Sanofi Pasteur, a Sanofi Company | 2011-12-01 |
| Sequential Inactivated Poliomyelitis Vaccine Followed by Oral Poliomyelitis Vaccine Versus Oral Poliomyelitis Vaccine (NCT01475539) | Sanofi Pasteur, a Sanofi Company | 2011-11-01 |
| Study of SP059 Given Subcutaneously as a Three-dose Primary and Booster Vaccination in Infants in Japan (NCT01389687) | Sanofi Pasteur, a Sanofi Company | 2011-07-01 |
| Study of DTap-IPV Compared to DAPTACEL® and IPOL® as the 5th Dose in Children 4 to 6 Years of Age (NCT01346293) | Sanofi Pasteur, a Sanofi Company | 2011-04-01 |
| A Safety Study of IMOVAX Polio Vaccine in Selected Cities in China (NCT01278433) | Sanofi Pasteur, a Sanofi Company | 2010-12-01 |
| A Study of the Safety of IMOVAX Polio™ in China (NCT01244464) | Sanofi | 2010-11-01 |
| Surveillance Program to Determine Product Specific Rates of Invasive Hib Disease (NCT00855855) | Sanofi Pasteur, a Sanofi Company | 2009-02-01 |
| Study of Immunogenicity and Safety of a Booster Dose of DTaP-IPV-HB-PRP~T Combined Vaccine in Healthy Turkish Infants (NCT00619502) | Sanofi Pasteur, a Sanofi Company | 2007-12-01 |
| Immunogenicity and Safety Study of a Booster Dose (5th) of Diphteria-Tetanus-Pertussis-Polio Vaccine (NCT00514059) | Norwegian Institute of Public Health | 2007-04-01 |
| Seroimmunity 2007 and Sub Study of the Swedish Population Regarding Vaccine Preventable Disease (NCT00932269) | Swedish Institute for Infectious Disease Control | 2007-03-01 |
| Comparison of a DTaP-IPV-HB-PRP~T Combined Vaccine to Infanrix™-Hexa, When Administered With Prevnar® in Thai Infants (NCT00401531) | Sanofi Pasteur, a Sanofi Company | 2006-10-01 |
| Comparison of DTaP-IPV-Hep B-PRP~T Combined Vaccine to CombAct-HIB® Concomitantly Given With Engerix B® Paediatric and OPV (NCT00362336) | Sanofi Pasteur, a Sanofi Company | 2006-08-01 |
| Study of PR5I, a Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar® (NCT00362427) | Sanofi Pasteur, a Sanofi Company | 2006-08-01 |
| Immunogenicity of DTaP-IPV-Hep B-PRP~T Combined Vaccine Compared With PENTAXIM™ and ENGERIX B® at 2-3-4 Months Schedule (NCT00315055) | Sanofi Pasteur, a Sanofi Company | 2006-07-01 |
| Immunogenicity and Safety of Imovax Polio in Chinese Infants Compared to Local OPV (NCT00348387) | Sanofi Pasteur, a Sanofi Company | 2006-06-01 |
| Immunogenicity and Safety of Pentaxim™ in an Indian Population (NCT00259337) | Sanofi | 2006-02-01 |
| Safety and Immune Response of Different Pediatric Combination Vaccines. (NCT00255047) | Sanofi Pasteur, a Sanofi Company | 2005-11-01 |
| Study of DAPTACEL® Administered as a 5th Dose in 4 to 6-Year-Old Children Previously Immunized With PENTACEL™ (NCT00802867) | Sanofi Pasteur, a Sanofi Company | 2004-02-01 |
| Assessment of the Immunogenicity and Safety of PENTAXIM™ in Philippines (NCT00254917) | Sanofi | 2003-10-01 |
| Study of the Effect of Pneumococcal Conjugate Vaccine (PCV) on Immunogenicity of Pentacel™ (NCT00772928) | Sanofi | 2003-10-01 |
| Retrospective Survey of Safety of Fourth Dose Pentacel® in Children (NCT00772369) | Sanofi Pasteur, a Sanofi Company | 2003-09-01 |
| Study of the Safety, Immunogenicity and Lot Comparability of DAPTACEL When Administered With Other Recommended Vaccine (NCT00662870) | Sanofi | 2001-05-01 |